logoAiPathly

BioAge Labs

B

Leadership Team

BioAge Labs, a clinical-stage biopharmaceutical company, boasts a diverse and experienced leadership team driving its mission to develop therapeutic product candidates for metabolic diseases by targeting the biology of human aging. Key members include:

CEO and Co-Founder

  • Kristen Fortney, PhD: Serving as CEO, President, and Treasurer since April 2015. Her annual compensation is approximately $1.38 million, with a 3.38% direct ownership of company shares.

Co-Founder

  • Eric Morgen: Leads human cohort partnerships and computational efforts for drug target discovery. His background spans artificial intelligence, medicine, and computational biology.

Chief Medical Officer & Executive VP of Research

  • Paul Rubin: Heads clinical development of BioAge's aging-targeted therapies. He brings extensive experience from pharmaceutical and biotech industries.

Chief Financial Officer

  • Dov Goldstein: Brings over 20 years of strategic financial and operational experience in healthcare, having held leadership roles at various biotech companies.

Other Key Positions

  • Chief Business Officer & Therapeutic Area Head of Brain Aging
  • Senior Vice President of Regulatory Affairs
  • Senior Vice President of Translational Aging Biology
  • Chief Strategy Officer

Board of Directors

  • Jean-Pierre Garnier, PhD: Recently appointed Chair, former CEO of GlaxoSmithKline
  • James Healy, MD, PhD: Former Chair, continuing board member and managing partner of Sofinnova Investments The leadership team combines seasoned executives and visionary co-founders, each contributing significant expertise to advance BioAge Labs' innovative approach to treating age-related diseases.

Core Technology

BioAge Labs leverages a data-driven approach to understand and target the biology of human aging, focusing on cardiometabolic and age-related diseases. Their core technology encompasses several key components:

Data Collection and Analysis

BioAge Labs utilizes extensive longitudinal human longevity data, primarily from blood samples, including:

  • Proteomics: Analyzing 5,000 proteins
  • Metabolomics: Examining several thousand metabolites
  • Gene expression: Analyzing tens of thousands of gene expressions using RNA-Seq

AI and Machine Learning

Advanced AI and ML algorithms are employed to analyze the vast dataset, identifying key molecular factors that change with age and predict future health outcomes. This approach distinguishes between healthy and unhealthy aging profiles.

Longitudinal Omics and Functional Assessments

The platform integrates longitudinal omics data with serial functional assessments, modeling aging-related physical, cognitive, and functional decline. This method captures healthspan trajectories starting from healthy individuals.

Discovery and Development

BioAge's platform identifies translational drug targets by analyzing the complex interplay of biological pathways related to metabolic aging. An unbiased approach is used to identify targets, which are then validated through an in-house translational aging core in naturally aged mice.

Collaboration and Integration

The company collaborates with industry leaders like Novartis, combining their human longevity datasets with external expertise to discover and validate new therapeutic drug targets.

Bespoke Data Science Ecosystem

BioAge has developed a custom data science ecosystem utilizing AI and ML to generate insights from human aging cohorts, crucial for identifying and validating potential therapeutic targets. By integrating these elements, BioAge Labs aims to develop therapies targeting fundamental biological pathways of human aging, with the goal of improving health outcomes and increasing healthspan.

Industry Peers

BioAge Labs operates within the biotechnology industry, focusing on aging and age-related metabolic diseases. Key industry peers and competitors include:

UNITY Biotechnology

A significant competitor developing therapeutics targeting diseases of aging, listed on NASDAQ under the ticker symbol UBX.

FibroGen

Known for developing innovative therapeutics in areas such as anemia and fibrosis, aligning with BioAge Labs' focus on metabolic and aging-related diseases.

Amgen

A major biotechnology company with a robust pipeline of therapeutics targeting metabolic diseases, including obesity and related conditions.

Novo Nordisk

A prominent player in the biotechnology sector, with a strong focus on diabetes and obesity treatments, presenting significant competition in the metabolic diseases space.

Regeneron Pharmaceuticals

Known for its innovative approach to drug development, particularly in metabolic disorders, posing a challenge to BioAge Labs with cutting-edge technologies and therapies.

Vertex Pharmaceuticals

While primarily focused on rare diseases and genetic disorders, Vertex presents competition in the broader biotech space due to innovative approaches and significant resources.

Other Competitors

Additional companies in the broader biotechnology and healthcare space that may overlap with BioAge Labs' research areas include:

  • DiaCarta
  • Mission Bio
  • Quadrants Scientific These competitors highlight the dynamic and competitive nature of the aging and metabolic diseases biotechnology sector, driving innovation and advancements in therapeutic development.

More Companies

C

Coinbase

Coinbase Global, Inc., commonly known as Coinbase, is a leading American publicly traded company that operates a comprehensive cryptocurrency exchange platform. Founded in June 2012 by Brian Armstrong and Fred Ehrsam, Coinbase has grown to become the largest cryptocurrency exchange in the United States by trading volume. Key aspects of Coinbase include: 1. Remote-first operations: Since May 2020, Coinbase has operated entirely on a remote-first model, with its legal headquarters in Wilmington, Delaware. 2. Product offerings: - Coinbase: App for buying, storing, and trading cryptocurrencies - Coinbase Pro: Professional asset trading platform - Coinbase Wallet: App for accessing decentralized crypto apps (dapps) - Coinbase Prime: Trading platform for institutional customers - Coinbase Custody: Custody solution for institutional clients - USD Coin: Digital stablecoin pegged to the U.S. dollar - Coinbase Card: Debit Visa card for spending cryptocurrency - Coinbase Earn: Platform rewarding users with altcoins for learning about cryptocurrencies 3. Regulatory compliance: Coinbase is a regulated platform that adheres to anti-money laundering regulations and Know Your Customer (KYC) requirements. 4. User base and financials: As of 2020, Coinbase reported 43 million verified users, 7,000 institutions, and 115,000 ecosystem partners across over 100 countries. The company generated $1.14 billion in net revenue and $322 million in net income in 2020. 5. Security measures: Coinbase emphasizes security for user assets but notes that custodially held crypto assets could be subject to bankruptcy proceedings if necessary. 6. Global presence: Coinbase operates in several countries, including the UK, Switzerland, Canada, Ireland, Germany, and the United States, providing real-time market information, value-added services, and market infrastructure. Coinbase plays a significant role in facilitating cryptocurrency transactions globally and continues to expand its offerings and reach in the rapidly evolving cryptocurrency market.

A

AST SpaceMobile

AST SpaceMobile is a pioneering company focused on developing the first and only global cellular broadband network in space, designed to operate directly with standard, unmodified mobile devices. Founded in May 2017 by Abel Avellan, the company is based in Midland, Texas, USA. ## SpaceMobile Network The company's flagship project, SpaceMobile, aims to provide 4G/5G speeds globally, including areas with little to no coverage. This innovative network will allow existing smartphones to connect directly to satellites without modifications. ## Technology and Satellites AST SpaceMobile's technology utilizes flat phased-array antennas, as demonstrated in their test satellite, BlueWalker 3. This satellite features a 693-square-foot array with thousands of antennas and has successfully demonstrated two-way telephone calls and 4G/5G connectivity with unmodified smartphones. The company is also developing BlueBird commercial satellites as part of its larger constellation. ## Partnerships and Funding The company has secured significant partnerships and funding, including collaborations with major telecom operators such as Vodafone, Rakuten, AT&T, and Verizon. In 2020, AST SpaceMobile raised $110 million in a Series B investment round. The company went public in 2021 through a business combination with New Providence's special-purpose acquisition company (SPAC), raising $462 million. ## Regulatory Approvals AST SpaceMobile has received several regulatory approvals, including an experimental license for the BlueWalker 3 satellite from the FCC in May 2022 and authorization to launch and operate the frequencies for the BlueBird 1-5 satellite mission in August 2024. However, the FCC has not yet decided on allowing the company to operate in terrestrial cellular frequencies for commercial satellite-to-cell services. ## Operations and Market Impact The company started generating revenue through a U.S. Government contract in 2024 and expects substantial revenue from mobile network operators once the BlueBird satellites are fully operational. AST SpaceMobile has achieved significant milestones, including the world's first space-based two-way telephone call with unmodified smartphones. As of August 2024, the company's market cap exceeded $8 billion, reflecting investor confidence in its potential to address a vast market of over 2.8 billion subscribers through its agreements with major mobile network operators.

T

Together AI

B

Boston Dynamics